Chompoonut Auphimai

846 citations

26 papers · 438 indexed · h-index 14

Co-authors: Yong Poovorawan Preeyaporn Vichaiwattana Nasamon Wanlapakorn Nungruthai Suntronwong Thanunrat Thongmee Donchida Srimuan Sirapa Klinfueng Ritthideach Yorsaeng
Topics: SARS-CoV-2 and COVID-19 Research (15 papers)COVID-19 Clinical Research Studies (10 papers)Animal Virus Infections Studies (8 papers)
Cited by: Infectious Diseases Health Hepatology
Journals: PLoS ONE Scientific Reports The Journal of Infectious Diseases
Partner nations: Thailand United Kingdom United States

In The Last Decade

Chompoonut Auphimai

26 papers receiving 434 citations

Peers

Countries citing papers authored by Chompoonut Auphimai

Since Specialization

Citations

This map shows the geographic impact of Chompoonut Auphimai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chompoonut Auphimai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chompoonut Auphimai more than expected).

Fields of papers citing papers by Chompoonut Auphimai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chompoonut Auphimai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chompoonut Auphimai. The network helps show where Chompoonut Auphimai may publish in the future.

Co-authorship network of co-authors of Chompoonut Auphimai

This figure shows the co-authorship network connecting the top 25 collaborators of Chompoonut Auphimai. A scholar is included among the top collaborators of Chompoonut Auphimai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chompoonut Auphimai. Chompoonut Auphimai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Dynamic Changes in Hybrid Immunity over Six Months after Inactivated and Adenoviral Vector Vaccination in Individuals with Previous SARS-CoV-2 Infection 2024 ·Vaccines ·Nungruthai Suntronwong,Sitthichai Kanokudom,Chompoonut Auphimai,Thanunrat Thongmee,Suvichada Assawakosri,Preeyaporn Vichaiwattana,Ritthideach Yorsaeng,Thaneeya Duangchinda,Warangkana Chantima,(unknown),Pornjarim Nilyanimit,Donchida Srimuan,(unknown),Natthinee Sudhinaraset,Nasamon Wanlapakorn,Yong Poovorawan	3
2	Epidemiology and clinical characteristics of severe acute respiratory infections among hospitalized children under 5 years of age in a tertiary care center in Bangkok, Thailand, 2019–2020 2023 ·Heliyon ·Nasamon Wanlapakorn,Ilada Thongpan,(unknown),Preeyaporn Vichaiwattana,Chompoonut Auphimai,Donchida Srimuan,(unknown),(unknown),Stephen J. Kerr,Yong Poovorawan	7
3	Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination 2023 ·Heliyon ·Suvichada Assawakosri,Sitthichai Kanokudom,Nungruthai Suntronwong,Jira Chansaenroj,Chompoonut Auphimai,Pornjarim Nilyanimit,Preeyaporn Vichaiwattana,Thanunrat Thongmee,Thaneeya Duangchinda,Warangkana Chantima,(unknown),Donchida Srimuan,(unknown),Sirapa Klinfueng,Natthinee Sudhinaraset,Nasamon Wanlapakorn,Juthathip Mongkolsapaya,Sittisak Honsawek,Yong Poovorawan	5
4	SARS-CoV-2 Antibody Dynamics after COVID-19 Vaccination and Infection: A Real-World Cross-Sectional Analysis 2023 ·Vaccines ·Ritthideach Yorsaeng,(unknown),Nungruthai Suntronwong,Sitthichai Kanokudom,Jira Chansaenroj,Suvichada Assawakosri,Pornjarim Nilyanimit,(unknown),(unknown),(unknown),Chompoonut Auphimai,Preeyaporn Vichaiwattana,Sirapa Klinfueng,Thanunrat Thongmee,Donchida Srimuan,(unknown),Natthinee Sudhinaraset,Nasamon Wanlapakorn,Yong Poovorawan	8
5	Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study 2022 ·Human Vaccines & Immunotherapeutics ·Nasamon Wanlapakorn,Nungruthai Suntronwong,(unknown),Ritthideach Yorsaeng,Preeyaporn Vichaiwattana,Thanunrat Thongmee,Chompoonut Auphimai,Donchida Srimuan,Thaksaporn Thatsanatorn,Suvichada Assawakosri,Sitthichai Kanokudom,Yong Poovorawan	47
6	Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination 2022 ·The Journal of Infectious Diseases ·Suvichada Assawakosri,Sitthichai Kanokudom,Nungruthai Suntronwong,Chompoonut Auphimai,Pornjarim Nilyanimit,Preeyaporn Vichaiwattana,Thanunrat Thongmee,Thaneeya Duangchinda,Warangkana Chantima,(unknown),Donchida Srimuan,Thaksaporn Thatsanatorn,Sirapa Klinfueng,Ritthideach Yorsaeng,Natthinee Sudhinaraset,Nasamon Wanlapakorn,Juthathip Mongkolsapaya,Sittisak Honsawek,Yong Poovorawan	41
7	COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron 2022 ·Vaccines ·Nungruthai Suntronwong,Ritthideach Yorsaeng,Jiratchaya Puenpa,Chompoonut Auphimai,Thanunrat Thongmee,Preeyaporn Vichaiwattana,Sitthichai Kanokudom,Thaneeya Duangchinda,Warangkana Chantima,(unknown),Suvichada Assawakosri,Pornjarim Nilyanimit,Sirapa Klinfueng,(unknown),Donchida Srimuan,Thaksaporn Thatsanatorn,Natthinee Sudhinaraset,Nasamon Wanlapakorn,Yong Poovorawan	13
8	Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination 2022 ·International Journal of Infectious Diseases ·Suvichada Assawakosri,Sitthichai Kanokudom,Jira Chansaenroj,Nungruthai Suntronwong,Chompoonut Auphimai,Pornjarim Nilyanimit,Preeyaporn Vichaiwattana,Thanunrat Thongmee,Thaneeya Duangchinda,Warangkana Chantima,(unknown),Donchida Srimuan,Thaksaporn Thatsanatorn,Sirapa Klinfueng,Natthinee Sudhinaraset,Juthathip Mongkolsapaya,Nasamon Wanlapakorn,Sittisak Honsawek,Yong Poovorawan	13
9	Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine 2022 ·Vaccines ·Sitthichai Kanokudom,Suvichada Assawakosri,Nungruthai Suntronwong,Chompoonut Auphimai,Pornjarim Nilyanimit,Preeyaporn Vichaiwattana,Thanunrat Thongmee,Ritthideach Yorsaeng,Donchida Srimuan,Thaksaporn Thatsanatorn,Sirapa Klinfueng,Natthinee Sudhinaraset,Nasamon Wanlapakorn,Sittisak Honsawek,Yong Poovorawan	48
10	Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination 2022 ·Diagnostics ·Nungruthai Suntronwong,Suvichada Assawakosri,Sitthichai Kanokudom,Ritthideach Yorsaeng,Chompoonut Auphimai,Thanunrat Thongmee,Preeyaporn Vichaiwattana,Thaneeya Duangchinda,Warangkana Chantima,(unknown),Jira Chansaenroj,Pornjarim Nilyanimit,Donchida Srimuan,Thaksaporn Thatsanatorn,Natthinee Sudhinaraset,Nasamon Wanlapakorn,Juthathip Mongkolsapaya,Yong Poovorawan	13
11	Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine 2022 ·Vaccines ·Jira Chansaenroj,Nungruthai Suntronwong,Sitthichai Kanokudom,Suvichada Assawakosri,Ritthideach Yorsaeng,Preeyaporn Vichaiwattana,Sirapa Klinfueng,(unknown),Donchida Srimuan,Thaksaporn Thatsanatorn,Thanunrat Thongmee,Chompoonut Auphimai,Pornjarim Nilyanimit,Nasamon Wanlapakorn,Natthinee Sudhinaraset,Yong Poovorawan	11
12	Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data 2022 ·Vaccine ·Nasamon Wanlapakorn,Nungruthai Suntronwong,(unknown),Ritthideach Yorsaeng,Thanunrat Thongmee,Preeyaporn Vichaiwattana,Chompoonut Auphimai,(unknown),Sirapa Klinfueng,Natthinee Sudhinaraset,Yong Poovorawan	13
13	Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine 2022 ·Vaccine ·Sitthichai Kanokudom,Suvichada Assawakosri,Nungruthai Suntronwong,Jira Chansaenroj,Chompoonut Auphimai,Pornjarim Nilyanimit,Preeyaporn Vichaiwattana,Thanunrat Thongmee,Ritthideach Yorsaeng,Thaneeya Duangchinda,Warangkana Chantima,(unknown),Donchida Srimuan,Thaksaporn Thatsanatorn,Sirapa Klinfueng,Juthathip Mongkolsapaya,Natthinee Sudhinaraset,Nasamon Wanlapakorn,Sittisak Honsawek,Yong Poovorawan	7
14	Genetic diversity and evolution of enterovirus A71 subgenogroup C1 from children with hand, foot, and mouth disease in Thailand 2021 ·Archives of Virology ·Jiratchaya Puenpa,Kamol Suwannakarn,Jira Chansaenroj,Chompoonut Auphimai,Nasamon Wanlapakorn,Sompong Vongpunsawad,Yong Poovorawan	5
15	Neutralizing antibody against Enterovirus-A71 in Thai children: A longitudinal study from birth to age 4 years 2020 ·Vaccine ·Jiratchaya Puenpa,Jira Chansaenroj,Chompoonut Auphimai,Donchida Srimuan,(unknown),Yong Poovorawan,Nasamon Wanlapakorn	2
16	Antibodies against measles and rubella virus among different age groups in Thailand: A population-based serological survey 2019 ·PLoS ONE ·Nasamon Wanlapakorn,Rujipat Wasitthankasem,Preeyaporn Vichaiwattana,Chompoonut Auphimai,Pornsak Yoocharoen,Sompong Vongpunsawad,Yong Poovorawan	15
17	Birth-cohort HCV screening target in Thailand to expand and optimize the national HCV screening for public health policy 2018 ·PLoS ONE ·Rujipat Wasitthankasem,Preeyaporn Vichaiwattana,(unknown),Nawarat Posuwan,Chompoonut Auphimai,Sirapa Klinfueng,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Kittiyod Poovorawan,Pisit Tangkijvanich,Yong Poovorawan	11
18	Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study 2018 ·PLoS ONE ·Rujipat Wasitthankasem,Preeyaporn Vichaiwattana,(unknown),Nawarat Posuwan,Chompoonut Auphimai,Sirapa Klinfueng,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Kittiyod Poovorawan,Pisit Tangkijvanich,Yong Poovorawan	13
19	High prevalence of coxsackievirus A2 in children with herpangina in Thailand in 2015 2017 ·VirusDisease ·Jira Chansaenroj,Chompoonut Auphimai,Jiratchaya Puenpa,(unknown),Nasamon Wanlapakorn,(unknown),Sompong Vongpunsawad,Yong Poovorawan	17
20	HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs 2017 ·PeerJ ·Rujipat Wasitthankasem,Preeyaporn Vichaiwattana,Chompoonut Auphimai,(unknown),Sirapa Klinfueng,Pisit Tangkijvanich,Sompong Vongpunsawad,Yong Poovorawan	23

About Chompoonut Auphimai

Chompoonut Auphimai is a scholar working on Infectious Diseases, Animal Science and Zoology and Hepatology, having authored 26 papers that have together received 438 indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (15 papers), COVID-19 Clinical Research Studies (10 papers) and Animal Virus Infections Studies (8 papers). The work is most often cited by research in Infectious Diseases (312 citations), Health (102 citations) and Hepatology (83 citations). Chompoonut Auphimai has collaborated with scholars based in Thailand, United Kingdom and United States. Frequent co-authors include Yong Poovorawan, Preeyaporn Vichaiwattana, Nasamon Wanlapakorn, Nungruthai Suntronwong, Thanunrat Thongmee, Donchida Srimuan, Sirapa Klinfueng, Ritthideach Yorsaeng, Sitthichai Kanokudom and Suvichada Assawakosri. Their work appears in journals such as PLoS ONE, Scientific Reports and The Journal of Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact